Similar Items: REVEAL AD ‐ Prevalence of Moderate and Severe Atopic Dermatitis in Ireland: A Cross‐ Sectional, Real World Study of a Secondary Care Population
- Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis)
- Corrigendum to “Effectiveness and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials”
- Corticosteroid Phobia in Patients with Atopic Dermatitis: A Narrative Review
- Efficacy of Upadacitinib in Patients with Atopic Dermatitis of the Head and Neck Region
- Clinically Meaningful Improvements in Quality of Life, Including Sleep, With Two‐Week and Monthly Dosed Rademikibart: A Phase 2 Randomized Trial in Adults With Moderate‐to‐Severe Atopic Dermatitis
- Efficacy of Lebrikizumab in Patients With Severe Atopic Dermatitis Who Would be Eligible for Treatment Based on the South Korean Reimbursement Criteria